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Breast cancer is increasingly being appreciated to be 
a complex disease. Pathologists have characterized 
18 distinct histopathological subtypes1 and compre-
hensive molecular profiling has revealed four major 
classes of breast cancer2; particularly clinically rele-
vant factors in this disease are tumour grade, hormone 
receptor status and the presence of ERBB2 (also known 
as HER2) amplification.
Evidence for enormous heterogeneity at the molec-
ular level continues to accumulate, with exon and 
whole-genome sequencing of several hundred breast 
carcinomas revealing the presence of, on average, 300 
mutations in the coding sequence per tumour but only 
a few genes that are frequently mutated across many 
tumours2,3. This raises complex questions about driver 
versus passenger mutations, tumour cell heterogeneity4 
and tumour evolution5.
The widely held view that mutations in breast epi-
thelial cells drive mammary carcinogenesis, however, 
is questioned by observations of the Danish patholo-
gist Maja Nielsen6. She sectioned entire breasts of 
women who had died of causes other than cancer and 
revealed that 30% of women in their forties had ductal 
carcinoma in situ (DCIS) or closely related precursor 
lesions6. The number of women who are actually diag-
nosed with breast cancer is substantially lower — one in 
eight (that is, 12.5%) — indicating that only a subset of pre-
cursor lesions will progress to clinically relevant disease. 
This is remarkable as DCIS is considered to be a direct 
precursor of invasive breast cancer, and comparative 
genomic hybridization has revealed the presence of 
extensive genetic alterations in DCIS that are similar 
to those found in nearby invasive lesions7. Thus, the 
presence of numerous mutations in breast epithelial 
cells, and even of a highly rearranged genome, is not 
sufficient to drive breast carcinogenesis. Additional 
factors must determine whether genetically altered cells 
progress to the state at which they provoke clinically 
manifest disease.
Experiments in mice and rats have shown that the 
ovarian steroid hormones, 17β‑oestradiol and proges-
terone, are pivotal in the control of breast develop-
ment and physiology8,9, and both experimental and 
epidemiological studies indicate that the two hor-
mones are intimately linked to mammary carcinogen-
esis. Hence, the dissection of their respective roles and 
understanding their mechanism of action could lead 
to the development of novel rational approaches for 
the prevention and treatment of breast cancer. The 
mouse mammary gland is a versatile experimental 
system that has been used to address these issues, in 
particular the complexities of endocrine versus para-
crine signalling. The rat model, which is generally 
considered closer to that of the human breast, con-
tinues to have an important role in carcinogenesis 
studies (BOX 1).
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17β-oestradiol
The predominant form of 
oestrogen in the human body it 
is more abundant than 
oestrone and oestriol both in 
terms of serum levels and 
oestrogenic activity.
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Abstract | Understanding the biology of the breast and how ovarian hormones impinge on it 
is key to rational new approaches in breast cancer prevention and therapy. Because of the 
success of selective oestrogen receptor modulators (SERMs), such as tamoxifen, and 
aromatase inhibitors in breast cancer treatment, oestrogens have long received the most 
attention. Early progesterone receptor (PR) antagonists, however, were dismissed because of 
severe side effects, but awareness is now increasing that progesterone is an important 
hormone in breast cancer. Oestrogen receptor-α (ERα) signalling and PR signalling have 
distinct roles in normal mammary gland biology in mice; both ERα and PR delegate many of 
their biological functions to distinct paracrine mediators. If the findings in the mouse model 
translate to humans, new preventive and therapeutic perspectives might open up.
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Aromatase inhibitors
Drugs that block aromatase, 
the enzyme that converts 
androgens to oestrogens in 
tissues, including the breast 
and adipose tissue. They are 
used to treat oestrogen 
receptor‑positive patients with 
breast cancer by decreasing 
circulating levels of oestrogenic 
compounds.
Hormone replacement 
therapy
(HRT). The administration of 
hormones to correct a 
deficiency, such as 
postmenopausal lack of 
oestrogen.
Reproductive hormones and breast cancer
Reproductive physiology. Centuries ago, breast cancer 
was considered to be a disease of nuns, a population 
that generally has a healthy lifestyle but uncommon 
reproductive behaviour. Epidemiological studies 
revealed that early full-term pregnancies lowered the 
risk of developing breast cancer10. More recently, this 
was shown to be specific to progesterone receptor (PR)-
positive breast cancers11, which represent the majority 
of breast cancers. For all types of breast cancer, risk 
increases with early menarche (the establishment of 
menstrual cycles), late menopause and shorter men-
strual cycles11; these factors all increase the number 
of menstrual cycles a woman experiences during her 
lifetime and hence the exposure time of the mammary 
epithelium to ovarian hormones.
The effect of menstrual cycles on breast cancer pro-
gression is strikingly illustrated by comparing the age-
specific incidence of colon cancer with that of breast 
cancer. The incidence of both cancers increases expo-
nentially up to the age of 50 — the average age at meno-
pause — after which the increase continues unabated 
for colon cancer but slows for breast cancer. It has been 
estimated that six times as many women would succumb 
to breast cancer if there were no menopause12.
The hypothalamic–pituitary axis triggers changes in 
ovarian hormone levels during every menstrual cycle, 
with a pre-ovulatory, follicular phase characterized by 
an oestrogen peak, followed by a post-ovulatory, luteal 
phase, during which the body prepares for a potential 
pregnancy; the luteal phase is characterized by a smaller 
oestrogen peak and by high levels of progesterone (FIG. 1). 
If pregnancy occurs progesterone levels rise further; 
because of its high levels and prominent role through-
out pregnancy, progesterone has been dubbed the 
‘pregnancy hormone’.
Several lines of evidence suggest that repeated expo-
sure to luteal phase, and hence to increased serum pro-
gesterone levels, increases breast cancer risk. First, the 
breast is quiescent during the first part of the menstrual 
cycle, the follicular phase. A lot of confusion arises from 
calling the first part of the cycle the ‘proliferative phase’. 
This term, however, is based on the changes that occur 
in the uterus: the endometrium proliferates before ovu-
lation. Post-ovulatory secretion of progesterone has anti-
proliferative effects on the endometrium and induces 
secretory differentiation in the uterine lining (FIG. 1). 
In the breast, cell proliferation occurs during the luteal 
phase, and is accompanied by changes in the stroma13,14. 
Furthermore, this proliferation happens in the terminal 
ductal lobular units (TDLUs), anatomical structures at 
the distal ends of the human milk ducts. The finding that 
all breast cancers originate in the TDLUs, regardless of 
whether their histopathological label is ‘lobular’, ‘ductal’ 
or other15, suggests that the changes during the luteal 
phase are related to the origin of breast cancer. Finally, 
the luteal phase is consistently 14 days long, whereas the 
duration of the follicular phase varies and is usually 
in the range of 10 to 21 days. Hence the increased risk 
of cancer that is related to shorter menstrual cycles 
correlates with more time spent in luteal phase.
Hormonal intervention. More than a century ago, the 
British surgeon George Beatson described regression of 
a breast tumour following ovariectomy16. In the 1960s, 
pharmacological antagonists of both oestrogen and pro-
gesterone were developed. PR antagonists failed in the 
clinic because of severe side effects, such as liver toxicity. 
By contrast, drugs that interfere with oestrogen signal-
ling, such as tamoxifen, which was introduced in the 
1970s, and aromatase inhibitors, which were introduced 
20 years later, have become mainstays of breast cancer 
therapy; they substantially prolong survival and have 
saved many lives17.
Agonists for both receptors have been developed and 
are used for both contraception and hormone replace‑
ment therapy (HRT), but there are growing concerns 
that they may increase breast cancer risk. Women cur-
rently taking oral contraception are at an increased risk 
of breast cancer18. However, the term oral contracep-
tion covers a plethora of approaches, with natural hor-
mones and synthetic agonists in different doses taken 
according to a multitude of regimens. Most studies do 
Box 1 | The rat model
In general, the physiology of the rat more closely 
resembles human physiology than does the mouse. In 
particular, similarities in liver metabolism make the rat a 
popular model for preclinical drug discovery and 
toxicological studies.
The rat has been the mammary tumour model of choice 
for decades because tumours that mimic the histology of 
some human breast cancer subtypes can be reproducibly 
induced by chemical carcinogenesis, and these tumours 
show hormone dependence91 and express hormone 
receptors92. Tumours that develop in the mouse 
mammary gland are mostly oestrogen receptor-α (ERα)
negative.
Importantly for mammary gland studies, the rat 
oestrous cycle is longer and more regular than that of 
mice, and pre-ovulatory and post-ovulatory phases can 
be readily distinguished. Furthermore, morphologically, 
the rat mammary gland bears more resemblance to the 
human breast than does the mouse mammary gland.
At a glance
•	Mutations are not always sufficient to drive breast carcinogenesis but additional 
factors determine whether genetically altered cells progress to the state during 
which they provoke clinically manifest disease.
•	The ovarian steroid hormones, 17β-oestradiol and progesterone, are pivotal in the 
control of breast development and physiology and are intimately linked to mammary 
carcinogenesis. Their respective roles in vivo have begun to be dissected in the 
mouse model.
•	17β-oestradiol and progesterone act on a subset of cells that express the respective 
receptors and elicit paracrine signalling.
•	Progesterone has emerged as the major mitogen in the adult mammary epithelium in 
both	mice	and humans.
•	The major proliferative control axis progesterone–receptor activator of nuclear 
factor-κB (NF-κB)	ligand	(RANKL)	is	conserved	between	mice	and humans.
•	Interfering with progesterone receptor (PR) signalling and paracrine signalling holds 
promise	for	breast	cancer	prevention	and therapy.
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not distinguish between these approaches, which could 
affect breast cancer risk in different ways. Moreover, it 
is conceivable that more differentiated analyses would 
identify risk factors, such as a woman’s age or repro-
ductive status, that are specific to particular types of 
contraception.
Women receiving HRT have little or no increase in 
breast cancer risk when taking oestrogens only, in fact 
there may even be a protective effect19. By contrast, a 
substantial increase in breast cancer risk was noticed 
in women taking combinations of an oestrogen and 
various synthetic progesterone agonists (progestins), 
despite this being standard of care in the United States 
and the United Kingdom20–22. This could be related to the 
increase in cell proliferation in the breast epithelium that 
has been reported with combination therapy23.
Studies from France revealed that postmeno pausal 
women who took natural progesterone instead of syn-
thetic progestins showed no statistically significant 
increase in breast cancer risk and that risk depends on 
the type of progestin used24,25. Progestins have longer 
half-lives than the unstable progesterone. This suggests 
that duration, level and molecular details of PR acti-
vation are important. Moreover, some progestins can 
bind to other nuclear receptors, including the androgen 
and the glucocorticoid receptors26, which further com-
plicates the analysis. Alternatively, there may be spe-
cial features of the postmenopausal breast that render 
it particularly susceptible to the effects of progestins 
but not to the effects of progesterone. The decline in 
the use of HRT that followed the publication of these 
results has already caused a decrease in breast cancer 
incidence27 and, more specifically, the increased risk 
related to the use of oestrogen plus progestin declined 
soon after its discontinuation28. An interesting poten-
tial explanation is that progestin exposure promotes the 
progression of pre-existing lesions to invasive cancer, 
which is in line with Nielsen’s findings6. Finally, high 
mammographical breast density, one of the strongest 
risk factors for breast cancer29,30 was correlated with 
progestin intake31–33.
Breast and mammary gland development
The mechanisms by which oestrogens and progesterone 
act in vivo are difficult to disentangle because of the 
complexities of endocrine regulation with multiple inter-
actions at the molecular, cellular, tissue and organismal 
levels. The breast is the only organ to develop mostly 
after birth, making it readily amenable to experimental 
manipulation. In addition, the mouse model provides 
unique experimental opportunities. Until puberty the 
mouse mammary gland consists of a rudimentary ductal 
system that is embedded in fatty stroma linked by a sin-
gle primary duct to the nipple. At puberty, the milk ducts 
begin to expand into the mammary fat pad. During 
adulthood, with repeated oestrous cycles, the ductal sys-
tem gains in complexity through side branching, which 
is strongly increased during early pregnancy. The last 
week of pregnancy is characterized by the sprouting of 
saccular outpouchings, called alveoli, which are destined 
to become sites of milk secretion (FIG. 2).
The anatomical structure of the human breast is 
more complex than the mouse mammary gland, with 
10–25 primary ducts emanating from each nipple; these 
branch extensively and give rise to lobes. At the end of 
the ducts are the TDLUs, which are bottlebrush-like, 
branched structures that are surrounded by specialized 
intralobular stroma. Unlike the homogeneous adipose 
mammary stroma of the mouse, the human stroma is 
made of loose connective tissue that is highly vascular-
ized and is separated from the interlobular stroma by 
fibrous connective tissue.
Role of progesterone versus oestrogens
Hormone ablation and replacement. Levels of endo-
genous progesterone and oestrogens can be depleted by 
ovariectomy, a simple surgical intervention in the mouse. 
As a result, cell proliferation in the mamm ary epithelium 
ceases and the epithelium eventually becomes atrophic. 
Experiments with such hormone-depleted animals 
have revealed that the administration of 17β-oestradiol 
is sufficient to induce cell proliferation in the pubertal 
gland, ultimately restoring ductal outgrowth, as is seen 
in intact pubertal animals34. However, when adult mice 
are ovariectomized and stimulated with 17β-oestradiol, 
the hormone barely induces any cell proliferation in the 
mammary gland35, whereas the combination of proges-
terone with 17β-oestradiol elicits substantial cell prolifer-
ation in adult mice that peaks at 48 hours of stimulation36. 
Little PR expression is detectable in ovariectomized mice37, 
Figure 1 | The menstrual cycle: serum hormone levels during a typical menstrual 
cycle together with changes in the breast. Note that the widely used term 
‘proliferative phase’ is based on the uterine cycle during which the endometrium builds 
up before ovulation. In the breast, cell proliferation is observed during the post-ovulatory 
and luteal phase. The two major ovarian hormones, the oestrogens and progesterone, 
are closely intertwined. FSH, follicle-stimulating hormone; LH, luteinizing hormone.
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and progesterone on its own elicits little prolifera-
tion within 48 hours. This is expected because oestro-
gens are required for PR expression in the mammary 
epithelium36. At later time points (3, 5 and 10 days) 
proliferation in response to progesterone stimulation 
is observed38; however, with longer experimental hor-
mone stimulation, levels of endogenous hormones may 
change, which could confound the analysis. Despite the 
caveat that ovariectomy creates nonphysiological con-
ditions, these findings strongly suggest that oestrogens 
drive pubertal development, whereas progesterone is 
the major stimulus for cell proliferation in the adult 
mammary gland.
Genetic approaches. Mice either lacking oestrogen 
receptor-α (ERα) or both isoforms of PR (BOX 2) have 
been generated through gene targeting in the germ line. 
Both mouse strains are viable but the mutant females 
have complex endocrine abnormalities39,40. Tissue 
recombination experiments with either mutant mam-
mary stroma or epithelium grafted into endocrine-
competent animals (FIG. 3) showed that epithelial ERα 
signalling41 and epithelial PR42 signalling are required 
at subsequent stages of mammary gland development 
(reviewed in REF. 43). Indeed, in the absence of epithelial 
PR signalling in an otherwise PR-intact adult mouse, cell 
proliferation in the mammary epithelium is minimal35. 
Simplistically, it seems from the genetic experiment 
that ERα signalling, the main driver of pubertal growth, 
is relegated to a permissive function, as it is required 
for epithelial PR expression. However, because of the 
developmental block imposed by the germline deletion, 
additional functions at later stages could be masked. 
Resolving this issue awaits studies with lineage-specific 
conditional ERα deletion.
Mouse versus human. The usefulness of the mouse as a 
model for human disease is debated because of differences 
in the physiology and organ morphology between the two 
species. With regards to the hormonal regulation of the 
mammary gland, the findings in the mouse mentioned 
above are reminiscent of what can be observed in humans. 
The breast epithelium is quiescent during the follicular 
phase when serum oestrogen levels peak. Cell prolifera-
tion is observed during the luteal phase when high serum 
progesterone levels prevail. In fact, hormonal secretion 
follows a similar pattern in the two species, with a pro-
gesterone peak after ovulation44. However, the oestrous 
cycles of mice are not regular and are poorly delineated45.
The sequential requirement for the two hormones 
during development seems to be conserved: thelarche, 
the onset of breast growth in girls, is associated with 
Figure 2 | Whole-mount stereographs of mouse inguinal mammary glands depicting distinct stages of mammary 
gland development. Until puberty the mammary gland consists of a rudimentary ductal system. The position of the 
nipple is indicated by arrowheads. During puberty ducts grow in the mammary fat pad by bifurcating. In adulthood, with 
repeated oestrous cycles, ductal complexity increases through side branching (arrows in pregnancy day 8.5 panel), 
which is enhanced during pregnancy. Later during pregnancy, alveologenesis (arrows in pregnancy day 14.5 panel) leads 
to an extensive increase in functional surface that is required for the secretion of copious amounts of milk during 
lactation. On weaning, the mammary gland involutes, which involves massive apoptosis, and returns to a pre-pregnancy 
state. LN, inguinal lymph node.
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Myoepithelial cells and 
basal cells
The two terms are often used 
interchangeably, but strictly 
speaking myoepithelial cells 
express markers for α‑smooth 
muscle actin (αSMA), 
caldesmon, p63 and 
cytokeratin 5 or cytokeratin 6 
and other high molecular mass 
cytokeratins. Basal cells are all 
the cells that do not touch the 
lumen hence they include 
subluminal cells and 
myoepithelial cells.
Luminal cells
Cells that touch the lumen of 
the mammary ductal system.
increasing ovarian oestrogen secretion and precedes 
menarche, which reflects the onset of cyclic proges-
terone secretion. Mice and humans differ substantially 
in the details of their hormonal physiology; they have 
different hormone levels, different hormone process-
ing by liver enzymes; different metabolites; and differ-
ent regulation of aromatase, the enzyme that converts 
circulating androgens to oestrogens locally in the 
breast46.
Global gene expression profiling of the response 
to oestrogens and progesterone in mouse and human 
model systems has shown poor overlap and led to the 
suggestion that there are species-specific differences 
in hormonal regulation and downstream signalling. 
However, the experimental approaches also differed 
substantially in that most human work was carried 
out using cultured cells, whereas the work in mice was 
generally carried out in the whole organism. We have 
recently developed an ex vivo approach using reduc-
tion mammoplasty specimens and shown that in fresh 
breast tissue microstructures progesterone elicits cell 
proliferation whereas 17β-oestradiol does so only 
in a subset of the breast tissue samples47. Moreover, 
important downstream mediators of PR signalling that 
were identified in the mouse mammary gland but that 
were not induced in human three-dimensional cul-
tures were also induced in the tissue microstructures 
that maintain cellular interactions. This suggests that 
the mouse mammary gland response to hormones is 
more similar to the human response than previously 
appreciated.
Cellular mechanisms of steroid action
Cell-intrinsic proliferation versus paracrine prolifera-
tion. Across species, ERα and PR are absent from the 
myo epithelial cells and basal cells and are expressed by 
30–50% of the luminal cells48,49. Most cells co-express 
ERα and PR, which is consistent with PR being an ERα 
target. A small subset of cells expresses either only 
ERα or only PR; whether this means a subset of cells 
uses a single receptor or whether it merely reflects the 
expression of these receptors at levels below the detec-
tion limit of immunohistochemistry is unclear. To sim-
plify, I refer to cells expressing one or both receptors 
as hormone receptor-positive (HR+) cells throughout. 
Studies in which freshly isolated, healthy human breast 
tissue samples were labelled with radioactive thymi-
dine to mark proliferating cells revealed that most of 
the breast epithelial cells that incorporated the marked 
nucleotides were ERα- and PR-negative cells48. This 
dissociation of proliferation and HR expression was 
subsequently demonstrated in vivo, both in mice and 
in rats50,51, and this led to the suggestion that HR+ cells 
function as organizers that may instruct their neigh-
bours. The low propensity of HR+ cells to prolifer-
ate has been linked to the presence in the subjacent 
extracellular matrix (ECM) of processed transforming 
growth factor-β (TGFβ) that activates TGFβ receptor 
(TGFβR) signalling, leading to the accumulation of 
phosphorylated SMAD2 and SMAD3 in the nucleus52.
Genetic evidence from mouse models indicates 
that steroid hormones can indeed act by paracrine 
mechanisms; either Esr1−/− (which encodes ERα) or 
Pgr−/− (which encodes PR) mammary epithelial cells 
derived from the respective mutant animals, were 
mixed with wild-type cells to generate chimeric epi-
thelia in cleared mammary fat pads. Receptor-deficient 
cells injected together with wild-type cells were able 
to contribute extensively to all aspects of mammary 
gland development. By contrast, receptor-deficient 
cells injected on their own could not41,42. Interestingly, 
when intact pieces of epithelial tissue from Pgr−/− or 
wild-type animals were co-transplanted into the same 
fat pad, no rescue occurred, indicating that the Pgr−/− 
mammary epithelial cells need to be in close proxim-
ity to wild-type cells for rescue to occur42. Hence, the 
factors implicated are not widely diffusible but func-
tion in a paracrine manner. This makes secreted fac-
tors such as WNTs, fibroblast growth factors (FGFs) 
and epidermal growth factor (EGF) family members 
attractive candidates but is also compatible with direct 
intercellular signalling mediated by Notch, ephrins or 
gap junctions.
Amphiregulin is an essential paracrine mediator of 
the cell proliferation induced by ERα at puberty53 and 
has also been linked to PR signalling in the rat mammary 
gland54; WNT4 and receptor activator of nuclear factor-κB 
(NF-κB) ligand (RANKL; also known as TNFSF11) have 
been established as important paracrine mediators of PR 
signalling35,55,56. Many other proteins have been implicated 
in mammary gland development by genetic experiments43 
but how they connect to hormonal control mechanisms 
remains to be established in most cases.
Sensors and responders. Thus, the HR+ cells seem to 
act as ‘sensor’ cells that translate the signals encoded by 
systemic hormones into local paracrine signals. To relay 
these signals they secrete paracrine factors that bind to 
receptors on HR–, luminal and basal cells, which act as 
the ‘secondary responder cells’. This organizing princi-
ple ensures that the signal is amplified and prolonged 
in time and provides a means of coordinating different 
biological functions of distinct cell types.
On the basis of elegant experiments in MCF-7 cells 
that showed rapid degradation of ERα after activation 
by ligand and by DNA binding57 it was thought that HR 
Box 2 | Progesterone receptor isoforms
Progesterone receptor (PR) is expressed as two isoforms, 
PRA and PRB. PRB contains an additional 164 amino 
acids at the amino terminus. The two isoforms are 
generally expressed at similar levels in the breast but  
the ratio can be altered in human breast tumours,  
with the PRA isoform predominating93. Isoform-specific 
mouse mutants were generated and revealed that PRB is 
the functionally important form in the mammary gland, 
whereas PRA is important for ovarian function94. In 
reporter assays the two forms have distinct but 
overlapping transcriptional activities95. They have also 
been reported to be differentially expressed during 
mammary gland development96.
R E V I E W S
NATURE REVIEWS | CANCER  VOLUME 13 | JUNE 2013 | 389
© 2013 Macmillan Publishers Limited. All rights reserved
Nature Reviews | Cancer
a
b c
Ductal 
tree
Three-week old
mammary gland
Cleared fat pad Reconstituted 
mammary gland
Piece of milk duct
Esr1 –/– Esr1+/+
Virgin
Day 14.5
MTWT
Bromodeoxyuridine
(BrdU). An analogue of 
thymidine that can be 
incorporated into the newly 
synthesized DNA of replicating 
cells and is used to detect 
proliferating cells.
expression was a transient cellular property; in other 
words, if a cell had recently been stimulated by oestro-
gens it would be HR–. Increasing evidence points to 
HR expression in vivo being a hallmark of a distinct 
cell type in the mammary epithelium. Strong support 
for this model comes from fluorescence-activated cell 
sorting (FACS) experiments, in which dissociated mam-
mary cells were separated on the basis of differences in 
cell surface antigen expression. High CD24 glycopro-
tein expression marks luminal cells, whereas low CD24 
expression marks myoepithelial cells58. The luminal 
CD24hi cells can be further separated on the basis of the 
expression of the cell surface marker stem cell antigen 1 
(SCA1; also known as LY6A)59. The SCA1+ population is 
enriched for HR+ cells, whereas the SCA1– population 
comprises HR– cells; the two populations have distinct 
gene expression signatures that go well beyond ERα and 
PR target genes60. The HR– cells seem to be destined 
for milk secretion, as they show increased expression 
of milk protein genes and of the ETS-related transcrip-
tion factor ELF5 that has been linked to the formation 
of secretory alveoli61. It is, however, conceivable that 
these expression signatures represent the sum of dif-
ferent subpopulations, HR+ or HR–, which remain to 
be characterized.
The idea that HR status also defines different cell 
types in humans is supported by global gene expres-
sion profiling of breast tumours62. The major molecular 
subtypes are thought to reflect the stage in the mam-
mary lineage from which the tumour was derived: a 
clinically rare stem cell-like type called claudin-low63; 
an ER– type resembling luminal progenitors called 
basal-like; and two differentiated types, an ER– type 
called molecular apocrine64, and finally the most 
common of breast tumours, an ER+ type called lumi-
nal. ERBB2-positive tumours are equally distributed 
between the two differentiated types. As the basal-like 
tumours are negative for steroid receptors (ER and PR) 
and ERBB2, they are commonly called triple-negative 
breast cancer (TNBC).
Progesterone-induced changes
Given that recurrent menstrual cycles and repeated 
progesterone exposure increase breast cancer risk, it is 
important to understand which pathways progesterone 
activates as it impinges on the adult mammary gland 
through the HR+ cells. The mechanisms by which proges-
terone triggers cell proliferation, activates progenitor cells, 
induces branching morphogenesis, affects immune 
cells, and controls the vasculature to ensure increased 
blood flow during the luteal phase and pregnancy are 
beginning to emerge in the mouse model (FIG. 4). I con-
centrate on the role of progesterone in cells in the HR+ 
cells — the sensor cells — in which ERα signalling is also 
active. Changes in oestrogen levels during the oestrous 
cycle impinge on all PR signalling activities and may be 
doing the fine-tuning (FIG. 4).
In contrast to tissues such as the skin or the intes-
tine where epithelial cells proliferate, differentiate and 
then shed, in the mammary gland, newly generated 
cells in the milk ducts are not automatically shed as 
part of the process of maturation. Increases in cell 
number are required for side branches to form in the 
mouse mammary gland and for TDLUs to increase in 
complexity in the human breast. There is some cell 
death at the end of each menstrual cycle, and massive 
apoptosis leading to the loss of alveolar structures after 
weaning (FIG. 2).
Cell proliferation. Stimulation of ovariectomized 
female mice with progesterone (after an oestrogen 
pretreatment that is required to induce PR expression) 
elicits a first, small wave of bromodeoxyuridine (BrdU) 
incorporation in PR+ cells, which is consistent with a 
cell-intrinsic mechanism (FIG. 5a). This is followed by 
a large wave of cell proliferation in PR– cells35 in line 
with the extra time required for synthesis and secretion 
Figure 3 | Tissue recombination approach. a | In prepubertal mice, the part of the 
inguinal mammary gland near the nipple that contains the rudimentary ductal system 
can be readily removed by surgery and the remaining ‘cleared fat pad’ can be engrafted 
with mammary epithelium from donor mice that will reconstitute. b | In this way, 
wild-type (WT) mice can be generated in which the epithelium of one inguinal mammary 
gland specifically lacks a given gene (the mutant (MT) gland) while the contralateral side 
is engrafted with wild-type epithelium. c | An example of an experiment in which 
oestrogen receptor-α (ERα)-deficient (Esr1–/–) and Esr1 wild-type epithelia derived from 
green fluorescent protein (GFP) transgenic females were grafted into contralateral 
cleared fat pads is shown. Mutant and wild-type grafts can be compared in a single host 
at different developmental stages such as puberty (top panels) and pregnancy day 14.5 
(bottom panels)41. Shown are fluorescent stereomicrographs of the engrafted glands, 
scale bar: 5 mm. Images are similar to those previously published in REF. 41.
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of a paracrine factor, and with the signal amplifica-
tion resulting from diffusion of this factor to multiple 
surrounding cells (FIG. 5b).
Cyclin D1 (encoded by CCND1) amplification and 
overexpression occur specifically in ER+ breast can-
cers65 and have been associated with a poor prognosis 
and endocrine resistance66–68, suggesting a unique role 
of cyclin D1 in the context of the HR+ cancers. To test 
whether cyclin D1 is particularly important in HR+ cells, 
mice with contralateral cleared fat pads were reconsti-
tuted with Ccnd1−/− versus wild-type epithelium, hor-
monally ablated and stimulated with progesterone35. The 
two types of proliferation, cell-intrinsic and paracrine 
proliferation, were observed in the wild-type graft but 
in the Ccnd1−/− epithelium proliferation of HR+ cells was 
specifically impaired. Thus, the cell-intrinsic action of 
progesterone on HR+ cell proliferation requires cyclin D1 
(FIG. 5a), whereas the proliferation of HR– cells does not 
(FIG. 5b). Whether this relates to the cell cycle function of 
cyclin D1, be it catalytic or through the sequestration of 
p21 and p27, or the interactions of cyclin D1 with hor-
mone receptors and their co-regulators (reviewed in 
REF. 69) remains to be elucidated.
Proliferation of HR– cells on progesterone stimu-
lation requires RANKL (FIG. 5b), a tumour necrosis 
factor-α (TNFα) family member that was first isolated 
as being important for dendritic cells, which was shown 
to be important for osteoclast function70. Subsequently, 
RANKL was implicated in mammary gland develop-
ment55. Its abrogation in the mammary epithelium of 
mice resulted in a lactation defect, which was linked 
to prolactin receptor signalling via inhibitor of NF-κB 
kinase-α (IKKα)71. However, RANKL expression 
is strongly induced by PR signalling and required 
for PR-induced side branching72,73. The protein is 
expressed specifically in PR+ luminal cells73. Induction 
of RANKL expression in ERα+ mammary epithelial 
cells of Pgr−/− females by means of an elegant inducible 
Figure 4 | Model: effect of menstrual cycles on breast cancer risk based on work in mouse models. Breast cancer risk 
is plotted over time, representative of a year during a woman’s reproductive age. Every hormonal cycle th re is ome 
increase in breast cancer risk when progesterone serum levels increase during the luteal phase as shown for a 
representative cycle (dashed box). Oestrogens induce the expression of the progesterone receptor (PR) and may have 
other functions that remain to be discerned, these probably involve fine-tuning of progesterone action at the level of 
transcriptional modulation. Several downstream mediators receptor activator of nuclear factor-κB (NF-κB) ligand 
(RANKL), cyclin D1, WNT4, calcitonin and inhibitor of DNA binding 4 (ID4) have been identified in the mouse. Genetic 
evidence has been provided that RANKL is required for progesterone-induced proliferation of hormone receptor (HR)– 
cells and cyclin D1 is required for cell proliferation of HR+ cells (bold grey arrows). RANKL has been implicated in the 
regulation of bipotential stem cells75,76 and shown to be required for side branching35. In Wnt4–/− and Id4−/− (REF. 82) 
mammary epithelia side branching is delayed. The role of calcitonin awaits further studies. Arrows in black indicate 
interactions that have been validated in humans43. ECM, extracellular matrix.
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double-transgenic approach, resulted in side branching 
and alveologenesis74. Similarly, ectopic RANKL expres-
sion in Pgr−/− mammary epithelium by means of a retro-
viral approach, rescued the Pgr−/− phenotype, indicating 
that RANKL is a crucial mediator of PR signalling func-
tion. Immunohistochemistry shows RANKL is present 
at the cell membrane, but whether it impinges on the 
neighbouring cells in this membrane-bound form or 
is secreted is unclear. Of clinical relevance, soluble 
RANKL administered intravenously can elicit prolifera-
tion in the mammary epithelium, and systemic admin-
istration of its decoy receptor osteoprotegerin (OPG) 
can inhibit proliferation35.
Mammary stem cells. FACS experiments combined with 
cleared fat pad reconstitution assays revealed that high 
expression of integrin α6 and integrin β1 enriches for 
cells with basal characteristics that are able to reconsti-
tute ductal trees in mammary fat pads devoid of endo-
genous epithelium. This led to the definition of these 
cells as mammary stem cells. Cells lacking these markers 
have luminal characteristics and fail to reconstitute 
ductal trees in cleared fat pads. Instead, they give rise 
to cystic structures58. Both oestrogens and progesterone 
were implicated in mammary stem cell activation on the 
basis of an increase in the number of integrin α6+ cells 
after hormone stimulation of ovariectomized mice75,76. 
RANKL was implicated in this hormone-induced stem 
cell expansion on the basis of the decreased in vitro clo-
nogenic capacity of integrin β1+ CD24+ cells harvested 
from mammary glands after in vivo treatment with an 
antibody against RANKL76. Furthermore, genetic abla-
tion of the RANKL receptor RANK abrogated a two-
fold increase in the integrin α6+ compartment induced 
by progestin treatment77, suggesting that RANKL may 
activate the stem cells as a paracrine factor.
Conversely, recent lineage-tracing experiments have 
provided evidence that the totipotent stem cell func-
tion may be provoked by the particular experimental 
conditions and may not be relevant to normal physio-
logical homeostasis. Indeed, luminally and myoepitheli-
ally restricted progenitors are sufficient to maintain the 
postnatal gland78,79. This raises the question of whether 
RANKL or the other paracrine factors such as WNT4 
and amphiregulin may function selectively on one or the 
other types of lineage-restricted progenitors.
Other biological functions and factors. Along with cell 
proliferation and the expansion of the progenitor cells, 
other biological processes are required to prepare the 
gland for copious milk production after the birth of pups 
in the mouse model. A large amount of ECM needs to 
be restructured in the process, and angiogenesis is 
required to feed new ducts and to subsequently bring 
in the nutrients that are necessary for milk production. 
Different types of immune cells help to build most of 
the transient structures required for lactation, and sub-
sequently help to destroy them and clear away the cel-
lular debris. Various matrix metalloproteinases (MMPs) 
and the associated tissue inhibitors of metalloprotein-
ases (TIMPs) have been implicated80 but how they are 
linked to hormonal pathways remains to be elucidated. 
A complex interplay between multiple cell types is to 
be expected. Powerful in vivo imaging approaches have 
shown us some of the activities of macrophages in the 
mammary gland81 and promise to provide novel insights 
in the future.
Genetic evidence has been provided that WNT4 
is an important mediator of PR signalling. In the 
absence of WNT4 from the mammary epithelium, 
side branching is delayed. Ectopic expression of its 
cousin WNT1 can rescue side branching by a par-
acrine mechanism in the absence of PR signalling56. 
Similarly, inhibitor of DNA binding 4 (ID4), a basic 
helix–loop–helix (bHLH) protein that is predomi-
nantly expressed in the myo epithelium is induced 
by progesterone, and its deletion in the mammary 
epithelium blocks side branching82. Calcitonin and 
amphiregulin have also been identified as in vivo pro-
gesterone targets83. Deletion of amphi regulin revealed 
a role for oestrogen-induced proliferation during 
pubertal ductal elongation53. This early phenotype 
Figure 5 | Models of cell-intrinsic and paracrine mechanisms of progesterone-
induced cell proliferation in the mouse mammary epithelium. A hormone receptor 
(HR)+ cell is indicated by a grey nucleus. Progesterone elicits proliferation of HR+ cells by a 
cell-intrinsic, cyclin D1-dependent mechanism (part a). The hormone also induces the 
expression of receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL) secretion, 
which triggers the proliferation of adjacent HR– cells (part b). Luminal and basal cells can 
be separated by fluorescence-activated cell sorting on the basis of high cell surface 
expression of CD24 or integrin β1 and integrin α6, respectively. The luminal (CD24hi) cell 
population can be divided into HR+ and HR– cells on the basis of the presence or absence 
of stem cell antigen 1 (SCA1). ER, oestrogen receptor; PR, progesterone receptor.
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imposes a developmental block that may mask any 
additional role during side branching. Therefore, defin-
ing the exact contributions of these different aspects 
of progesterone-induced differential gene expression 
will require further studies. The elucidation of these 
processes will provide us with important insights into 
the clinically relevant question of how in situ lesions 
progress to invasive disease.
Progesterone signalling and breast cancer
What are the implications of these findings for breast 
cancer? It is conceivable that during repeated menstrual 
cycles, recurrent activation of PR and its downstream 
effectors, cyclin D1, WNT4 and RANKL promotes 
breast carcinogenesis (FIG. 6). Indeed, administration of 
the PR agonist medroxy-progesterone acetate (MPA) 
to mice promotes the formation of mammary tumours 
initiated by DMBA84. Such MPA- and DMBA-induced 
tumorigenesis is slowed both by pharmacologically and 
by genetically interfering with RANKL signalling77,85. 
Constitutive activation of the well-established signal-
ling pathways downstream of PR is also oncogenic. 
Ectopic RANK expression in the mammary epithelium 
driven by the mouse mammary tumour virus (MMTV) 
promoter increases proliferation in the mammary epi-
thelium86 and accelerates DMBA- and progestin-induced 
tumorigenesis85.
Another downstream pathway, the WNT signalling 
pathway, has long been identified as oncogenic in the 
mouse mammary gland. In fact, the first WNT gene to 
be cloned was identified as a frequent integration site 
for MMTV87. Its ectopic expression results in extensive 
ductal hyperplasia and tumours88.
Using freshly isolated human breast tissue microstruc-
tures we have found that expression of both RANKL and 
WNT4 mRNA is induced by PR signalling47. Moreover, 
RANKL is sufficient to elicit cell proliferation and 
is required for progesterone-induced proliferation. 
The findings in the ex vivo system were validated by 
the in vivo observation that RANKL protein expression 
correlated with serum progesterone levels in women47.
These findings offer exciting perspectives as they 
suggest that at least some of the pathways are conserved 
between mice and humans and that they may contrib-
ute to tumorigenesis. Hence novel preventive strategies 
can be envisioned that are based on inhibiting PR and 
its downstream mediators RANKL and WNT. New-
generation selective progesterone receptor modulators 
(SPRMs) that have fewer side effects than earlier ones, 
have been developed for various gynaecological dis-
orders such as myomas, bleeding endometriosis and 
other reproductive problems, and may turn out to be 
useful for patients with breast cancer. Furthermore, an 
antibody against RANKL, denosumab, is already US 
Food and Drug Administration (FDA)-approved for 
the treatment of postmenopausal women who are at a 
high risk of fractures and for the prevention of skeletal 
complications in patients with bone metastases. WNT 
inhibitors are being developed and are undergoing 
clinical testing89.
Figure 6 | Model of breast carcinogenesis. Shown are schematic cross sections of a milk duct with l minal (beige) and 
outer myoepithelial cells (green) that are surrounded by a basement membrane (pink). Analogously to the Vogelstein 
model of colon cancer progression97, successive stages of breast tumorigenesis are shown. Early stages of breast 
carcinogenesis are poorly characterized. Hormones impinge on all stages of breast cancer development. In particular, 
progesterone signalling is important in determining whether pre-existing lesions progress to clinically relevant tumours; 
that is, invasive and metastatic breast cancer. Progesterone changes the microenvironment, and it activates a number of 
pathways that have been implicated in the genesis of different subtypes of breast cancer in the mouse mammary gland 
that control intercellular communication. I hypothesize that repeated activation of these pathways during the luteal 
phase of menstrual cycles promotes breast carcinogenesis. Some of these such as amphiregulin98, receptor activator of 
nuclear factor-κB (NF-κB) ligand (RANKL)99 and inhibitor of DNA binding 4 (ID4)100 have indeed been implicated in the 
genesis of distinct human breast cancer subtypes.
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Interfering pharmacologically with menstrual 
cycle-induced activation of the breast (as described 
above), may be of particular use in young patients 
with breast cancer. Women under 40 years of age 
who have breast cancer have a 5% risk of developing 
a second tumour in the contralateral breast within 
10 years. Interfering with the breast-specific effects 
of increased serum progesterone levels may be an 
effective way to reduce their risk of dying of breast 
cancer without blocking all reproductive function. 
SPRMs could also be envisioned as adjuvant treat-
ment in scenarios in which selective oestrogen receptor 
modulators (SERMs) or aromatase inhibitors are not 
well tolerated.
With regards to the ability of such drugs to act on 
established tumours and in advanced disease, impor-
tant questions need to be addressed. Are the paracrine 
mecha nisms discussed above active in human tumours? 
It is important to remember that ER+ tumours are 
defined by immunhistochemistry as having at least 1% 
of tumour cells that stain for ERα. Hence, they com-
prise a whole range of tumours with anything from 1% 
to 100% of the tumour cells expressing ERα. It is con-
ceivable that paracrine signalling is more important for 
tumours with a low proportion of ERα+ cells than for 
the majority of ERα+ tumours, which show widespread 
ERα expression. In ERα+ tumours ERα expression and 
thymidine incorporation coexist in a large proportion 
of the cells. Is this proliferation induced by cell-intrinsic 
and/or by paracrine mechanisms?
Are the paracrine loops active in the metastatic 
niche? Are they activated by ERα or PR expressed by 
the tumour cells or perhaps by hormone-responsive 
bone cells? In the MMTV‑Erbb2 tumour model, infil-
trating T cells have been shown to stimulate metastasis 
by releasing RANKL90, suggesting that paracrine loops 
also involve an immune cell component, at least in 
tumorigenesis.
HR– tumours generally do not respond to hormone 
therapy and are thought to bypass the requirement for 
hormones by constitutively activating cell-intrinsic 
growth-promoting pathways. The specific growth- 
promoting pathways chosen may represent a character-
istic of a particular tumour or a subset of cells within a 
given tumour. In their early stages, and possibly in the 
process of metastatic seeding, there may be hormone-
sensitive steps in their progression, as suggested by the 
finding that menstrual cycles increase the risk for all 
types of breast cancers.
Blocking the hormone-induced activation of a pro-
tumorigenic microenvironment, either in the breast or 
at distant sites in the body, by interfering with hormone 
signalling and downstream pathways, may help to pre-
vent disease progression. It could then form the basis 
of an adjuvant therapy in women diagnosed with early 
stage disease, many of whom are currently overtreated 
with chemotherapy.
Perspectives
Thanks to high-throughput sequencing approaches, our 
knowledge of the molecular genetics of breast cancer 
is increasing much faster than our understanding of 
mammary gland biology and pathology. Reproductive 
hormones impinge on breast carcinogenesis at all 
stages and can determine whether the disease will pro-
gress (FIG. 6). In particular, PR signalling has a pivotal 
role in controlling tumour promotion from the in situ 
stage onwards. The insight that systemic hormones 
use locally produced paracrine factors to mediate their 
effects offers new opportunities for intervention. Such 
novel approaches may allow us to ‘deactivate’ a tumour-
promoting microenvironment, an approach that may 
also help to prevent tumour progression and metastasis. 
How genetic mutations in tumour cells synergize with 
changes in the microenvironment elicited by hormones 
will be a challenging area to explore.
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